It’s one of the most anticipated conferences of the year.

Tens of thousands of oncology professionals, physicians, investors, and companies will converge at this year’s American Society of Clinical Oncology (ASCO) meeting in Chicago, Illinois, June 3-7, 2016.

And for smart investors, it’s a goldmine opportunity.

History has proven this is the place where biotech companies begin to reveal the latest information about oncology drugs, their latest trial results, and up-and-coming topics of interest, including the multi-billion dollar immunotherapy market.

But there’s a way to get that data goldmine long before the conference begins.

On May 18, 2016 at 5pm EST, ASCO will release key abstracts from some of the most highly sought after studies and sessions.  It’s an opportunity for investors to validate ideas that have been generating incredible buzz in the industry.

One of the biggest buzzwords you’ll hear again this year is immunotherapy.

ASCO 2016: Immunotherapy in the Spotlight

It’s a major force in cancer treatments that uses a person’s own immune system to fight cancer.  Although this therapy has been around for decades, it’s just now being viewed as an essential weapon in the fight. Rather than targeting specific cancer cells, it disables cancer defenses so a patient’s immune system can find it and destroy it.

Conventional therapies and other drugs may often have a substantial effect in shrinking cancer, but the effects can be short-lived. Immunotherapy treatments last longer because the immune system is being reset with a memory of exactly how to fight back.

Nowadays, estimates say immunotherapy could generate $35 billion in sales and help treat up to 60% of cancers over the next 10 years. 

With an estimated 1.68 million new cases of cancer likely to be diagnosed and more than 595,000 likely deaths this year, it’s a much-needed therapy. The most common cancers are expected to be breast, lung and bronchus cancer, prostate, colon and rectum cancer, too.  Worse, national expenditures in the U.S. totaled $125 billion in 2010.

It could reach $156 billion by 2020.

It’s why we’re watching what immunotherapy-related companies have to say in just a few short weeks, including Advaxis Inc. (ADXS), which will present Stage 1 of its Phase II study on ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer.

For some perspective, cervical cancer is the fourth most common cancer in women globally.  In the U.S. alone, about 13,000 new cases are diagnosed, with 4,100 deaths per year. Any positive data presented at ASCO could be a significant driver for the stock.

Genentech (DNA) will also present new trial results for atezolizumab, as well.  It will include data from a study where patients were administered the drug as an initial treatment for metastatic bladder cancer.  New overall survival and diagnostic results will be presented in recurrent metastatic bladder and lung cancers, too.

Artificially strengthening the immune system against cancer is one of the most exciting – profitable -- breakthroughs of our time.

Treatments such as these hold immense commercial potential with an apparent ability to change cancer treatments and survival rates, as we know it, offering smart investors some of the greatest opportunities of a lifetime.

Take advantage… The opportunity will only wait so long.

1 Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Post comment